185 related articles for article (PubMed ID: 37267457)
21. Metabolic fate and carcinogenicity of N-(omega-hydroxyalkyl) N-(4-hydroxybutyl) nitrosamines analogs of N-butyl-N-(4-hydroxy-butyl) nitrosamine, in the rat.
Suzuki E; Takeda Y; Mochizuki M; Hashimoto Y; Okada M
Gan; 1981 Aug; 72(4):539-46. PubMed ID: 7308665
[TBL] [Abstract][Full Text] [Related]
22. An update on the current status and prospects of nitrosation pathways and possible root causes of nitrosamine formation in various pharmaceuticals.
Wichitnithad W; Nantaphol S; Noppakhunsomboon K; Rojsitthisak P
Saudi Pharm J; 2023 Feb; 31(2):295-311. PubMed ID: 36942272
[TBL] [Abstract][Full Text] [Related]
23. Utilisation of parametric methods to improve percentile-based estimates for the carcinogenic potency of nitrosamines.
Thomas R; Thresher A; Ponting DJ
Regul Toxicol Pharmacol; 2021 Apr; 121():104875. PubMed ID: 33556416
[TBL] [Abstract][Full Text] [Related]
24. Nitroso Impurities in Drug Products: An Overview of Risk Assessment, Regulatory Milieu, and Control Strategy.
Charoo NA; Dharani S; Khan MA; Rahman Z
AAPS PharmSciTech; 2023 Feb; 24(2):60. PubMed ID: 36759424
[TBL] [Abstract][Full Text] [Related]
25. Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.
Burns MJ; Ponting DJ; Foster RS; Thornton BP; Romero NE; Smith GF; Ashworth IW; Teasdale A; Simon S; Schlingemann J
J Pharm Sci; 2023 Dec; 112(12):3005-3011. PubMed ID: 37805074
[TBL] [Abstract][Full Text] [Related]
26. Developing Structure-Activity Relationships for
Cross KP; Ponting DJ
Comput Toxicol; 2021 Nov; 20():. PubMed ID: 34901581
[TBL] [Abstract][Full Text] [Related]
27. Computational evidence for α-nitrosamino radical as initial metabolite for both the P450 dealkylation and denitrosation of carcinogenic nitrosamines.
Ji L; Schüürmann G
J Phys Chem B; 2012 Jan; 116(2):903-12. PubMed ID: 22136655
[TBL] [Abstract][Full Text] [Related]
28. Regiospecificity in the metabolism of the homologous cyclic nitrosamines, N'-nitrosonornicotine and N'-nitrosoanabasine.
Hecht SS; Young R
Carcinogenesis; 1982; 3(10):1195-9. PubMed ID: 7172419
[TBL] [Abstract][Full Text] [Related]
29. Stereoselective metabolism of nicotine and tobacco-specific N-nitrosamines to 4-hydroxy-4-(3-pyridyl)butanoic acid in rats.
Trushin N; Hecht SS
Chem Res Toxicol; 1999 Feb; 12(2):164-71. PubMed ID: 10027794
[TBL] [Abstract][Full Text] [Related]
30. Chemical studies on tobacco smoke LVI. Tobacco specific nitrosamines: origins, carcinogenicity and metabolism.
Hecht SS; Chen CB; Ornaf RM; Hoffmann D; Tso TC
IARC Sci Publ (1971); 1978; (19):395-413. PubMed ID: 680735
[TBL] [Abstract][Full Text] [Related]
31. Metabolic Activation and Carcinogenesis of Tobacco-Specific Nitrosamine N'-Nitrosonornicotine (NNN): A Density Function Theory and Molecular Docking Study.
Fan T; Sun G; Zhao L; Cui X; Zhong R
Int J Environ Res Public Health; 2019 Jan; 16(2):. PubMed ID: 30634532
[TBL] [Abstract][Full Text] [Related]
32. Carcinogenicity and metabolic activation of tobacco-specific nitrosamines: current status and future prospects.
Hecht SS; Castonguay A; Chung FL; Hoffmann D
IARC Sci Publ; 1984; (57):763-78. PubMed ID: 6398307
[TBL] [Abstract][Full Text] [Related]
33. DNA Adduct Formation from Metabolic 5'-Hydroxylation of the Tobacco-Specific Carcinogen N'-Nitrosonornicotine in Human Enzyme Systems and in Rats.
Zarth AT; Upadhyaya P; Yang J; Hecht SS
Chem Res Toxicol; 2016 Mar; 29(3):380-9. PubMed ID: 26808005
[TBL] [Abstract][Full Text] [Related]
34. NITROSAMINE CONTAMINATION WITHIN CARDIAC MULTIMEDICATION - SARTANS (VALSARTAN), CALCIUM CHANNEL BLOCKERS (AMLODIPINE AND NIFEDIPINE), AND ANTIARRHYTHMICS (PROPAFENONE) AS A SIGNIFICANT FACTOR IN THE DEVELOPMENT AND PROGRESSION OF MULTIPLE KERATINOCYTIC CANCERS: ADVANCEMENT ROTATION FLAP FOR KERATOACANTHOMA OF THE UPPER LIP AND UNDERMINING SURGERY FOR BCC OF THE SHOULDER AS AN OPTIMAL DERMATOSURGICAL APPROACH.
Tchernev G
Georgian Med News; 2023 Sep; (342):152-155. PubMed ID: 37991972
[TBL] [Abstract][Full Text] [Related]
35. Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in lung tissue from mouse, rat, hamster, and man.
Richter E; Engl J; Friesenegger S; Tricker AR
Chem Res Toxicol; 2009 Jun; 22(6):1008-17. PubMed ID: 19408892
[TBL] [Abstract][Full Text] [Related]
36. [Quantitative structure-activity relationship prediction of carcinogenicity of N-nitroso compounds based on category approach and read-across].
Liang QQ; Zheng WW; He GS; Qu WD
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Jul; 51(7):621-627. PubMed ID: 28693087
[No Abstract] [Full Text] [Related]
37. 7-azabicyclo[2.2.1]heptane as a structural motif to block mutagenicity of nitrosamines.
Ohwada T; Ishikawa S; Mine Y; Inami K; Yanagimoto T; Karaki F; Kabasawa Y; Otani Y; Mochizuki M
Bioorg Med Chem; 2011 Apr; 19(8):2726-41. PubMed ID: 21435887
[TBL] [Abstract][Full Text] [Related]
38. Hydroxylation of carbon atoms of the alkyl chain of symmetrical N-nitrosodialkylamines by rat liver microsomes.
Bellec G; Dreano Y; Pichon R; Ménez JF; Berthou F
Cancer Lett; 1996 Nov; 108(2):171-8. PubMed ID: 8973591
[TBL] [Abstract][Full Text] [Related]
39. Mutagenic impurities in pharmaceuticals: A critical assessment of the cohort of concern with a focus on N-nitrosamines.
Snodin DJ
Regul Toxicol Pharmacol; 2023 Jun; 141():105403. PubMed ID: 37116739
[TBL] [Abstract][Full Text] [Related]
40. Setting limits for N-nitrosamines in drugs: A defined approach based on read-across and structure-activity relationship for N-nitrosopiperazine impurities.
Dos Santos CEM; Dorta DJ; de Oliveira DP
Regul Toxicol Pharmacol; 2022 Dec; 136():105288. PubMed ID: 36384172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
